NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors

Marc McGowan¹, Lilach Kleinberg¹,², Ann Rita Halvorsen¹, Åslaug Helland¹,³, and Odd Terje Brustugun¹,⁴

¹ Department of Cancer Genetics, Radium Hospital – Oslo University Hospital, Oslo, Norway
² Department of Pathology, Oslo University Hospital, Oslo, Norway
³ Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Norway
⁴ Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway

Correspondence to: Odd Terje Brustugun, email: otr@vestreviken.no

Keywords: Drug-resistance, NSCLC, YAP, EGFR, EMT

Received: April 16, 2017  Accepted: May 21, 2017  Published: May 23, 2017

Copyright: McGowan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Yes-associated protein (YAP) is a downstream target of the Hippo pathway and has been found to be oncogenic driving many cancers into developing metastatic phenotypes leading to poor survival outcomes. This study investigated if YAP expression is associated with drug resistance in two non-small cell lung cancer (NSCLC) lines (HCC827 and H1975) generated to become resistant to the EGFR tyrosine kinase inhibitors (EGFR TKI) erlotinib, gefitinib or the T790M-specific osimertinib. We found that acquired EGFR TKI resistance was associated with YAP over-expression (osimertinib-resistant cells) or YAP amplification (erlotinib- and gefitinib-resistant cells) along with EMT phenotypic changes. YAP was localized in the nucleus, indicative of active protein. siRNA-mediated silencing of YAP resulted in re-sensitizing the drug-resistant cells to EGFR TKI compared to the negative siRNA controls (p = <0.05). These results suggest YAP is a potential mechanism of EGFR-TKI resistance in NSCLC and may presents itself as a viable therapeutic target.

INTRODUCTION

Innon-small cell lung cancer (NSCLC), responsible for the highest death toll among cancers [1], targeted therapy has been a remarkable success. Both EGFR-, ALK-, ROS1-directed therapies are approved, and about a fifth of all metastatic NSCLC patients may be offered such therapies with median responses of around a year [2]). However, progression due to acquired resistance is virtually inevitable, and a number of different resistance mechanisms are described [3]. In EGFR-mutated tumours treated with the first (erlotinib, gefitinib) or second (afatinib) generation EGFR tyrosine kinase inhibitors, the most frequent mechanism of resistance is a secondary mutation in exon 20 of the EGFR-gene; T790M [4]. Recently a drug targeting T790M-positive tumours, osimertinib, was approved after studies showing prolongation of progression free survival in EGFR-pre-treated and progressed patients harbouring T790M [5]. Still, a substantial fraction of tumours harbour other resistance mechanisms of which some, as AXL over-expression [6] and MET amplification [7, 8] are known, but others are still unknown and where no targeted therapies are available.

Yes-associated protein (YAP) has been found to both regulate the expression of Axl [9] and also drive the required phenotypic changes to cause epithelial to mesenchymal cell transformation (EMT) after binding with its transcriptional co-activator TEAD [10]. YAP expression is associated with reduced survival and relapse trends in NSCLC patients [11] which further highlights this co-transcription factor as an interesting target for drug-resistance research. But not much is known about YAP’s role in drug-resistance. This study presents a new view of YAP using the HCC827 (exon 19 E746-A750 deletion) NSCLC cell line generated to become resistant to first generation TKIs and H1975 (harbouring both the T790M and L858R mutation) to osimertinib.
RESULTS

Drug-resistant sub-lines

After proliferation was observed in the HCC827 gefitinib (GR) and erlotinib-resistant (ER) sub-lines they were isolated using cloning cylinders and expanded in individual colonies. Twenty-four sub-lines were generated and analysed for EGFR mutations outside of the exon 19 in frame deletion. Sequencing results showed no alterations from the HCC827 parental and drug-resistant sub-lines (data not shown). We randomly selected one erlotinib and one gefitinib sub-line for all further experiment. We determined the HCC827/ER and GR sub-lines were drug-resistant following a cell viability assay showing a shift in EC$_{50}$ values from the HCC827 parental line (Figure 1 A and B). We tested whether the third generation EGFR inhibitor osimertinib (formally AZD9291) was able to inhibit growth in the drug-resistant sub-lines compared to the parental controls using the cell viability assay. The results show a shift in EC$_{50}$ value from the drug-resistant cells compared to the parental (Figure 1 C).

The H1975 cell line is characterized by harbouring the EGFR gatekeeper mutation T790M in exon 20 that prohibits signalling inhibition by erlotinib and gefitinib. We generated three sub-lines resistant to osimertinib (referred to as H1975/OR), whereof one sub-line was selected at random for all further experiments. The cell viability showed a shift in EC$_{50}$ from the H1975 parental and H1975/OR – from 0.01 µM to ~2.5 µM – (Figure 1 D). We sequenced exons 18-21 of the EGFR gene for additional mutations but our results showed no alterations from the parental line (data not shown).

Resistant sub-lines promote EMT changes and Expression of YAP

The HCC827/ER sub-line showed markers of EMT (vimentin expression and loss of e-cadherin) and AXL expression after acquiring resistance to erlotinib. HCC827/GR sub-lines also showed AXL and vimentin expression but still some e-cadherin expression (Figure 2) compared to the HCC827/ER sub-line. The morphology of the sub-lines also differed where HCC827/ER were mesenchymal and differed from the parental, and HCC827/GR resembled their parental and did not appear to have undergone EMT. Interestingly, EGFR appeared to be down-regulated in the HCC827/ER sub-line when compared to HCC827/GR and parental line. We observed

---

Figure 1: EC$_{50}$ of HCC827GR, HCC827/ER, and H1975/OR sub-lines. A. There was a clear difference between drug-sensitive HCC827 parental (EC$_{50}$ = 0.004 µM) and gefitinib-resistant (GR) sub-line (EC$_{50}$ >10 µM). B. Erlotinib-resistant HCC827/ER showed the ability to proliferate in high concentrations of drug (EC$_{50}$ >10 µM) compared to the parental (EC$_{50}$ = 0.001 µM). C. The HCC827/ER, GR levels of tolerance to osimertinib. The HCC827/GR sub-line showed a greater tolerance to osimertinib (EC$_{50}$ = 1.4 µM) while the HCC827/ER had a lower tolerance (EC$_{50}$ = 0.8 µM). It was concluded that the cells not being completely resistant to osimertinib did show the ability degree to proliferate in higher concentrations than the parental line (EC$_{50}$ = 0.003 µM). D. The H1975/OR shows resistance to osimertinib (EC$_{50}$ = ~2.5 µM) compared to the H1975 parental (EC$_{50}$ = 0.008 µM).
YAP over-expression after acquiring resistance to the first generation EGFR inhibitors. Using RT-qPCR confirmed amplification of YAP at the mRNA level (data not shown). We then analysed if the overexpression of YAP resulted in the increased expression of its inhibitor Merlin. We found Merlin was not expressed in any of the HCC827 parental or drug-resistant sub-lines. The H1975/OR sub-line was tested for known resistant proteins (AXL, EGFR) as well as YAP expression (Figure 2). From the Western Blot the H1975 parental cells harboured AXL which was over-expressed in the H1975/OR sub-line. We saw YAP expression in the H1975/OR sub-lines and not in the parental. We further evaluated these findings with RT-qPCR which confirmed expression differences (data not shown). We then assessed if Merlin was also expressed in these cells. Interestingly, we observed co-expression of both YAP and Merlin in the H1975/OR drug-resistant sub-line. This was not observed in the HCC827 drug-resistant cells (ER or GR) and warranted further experimentation to determine if YAP was active.

Immunocytochemistry staining (ICC) was chosen to visualize if YAP was active (localized in the nucleus) or inactive (withheld in the cytoplasm). ICC results showed YAP was distributed in both cytoplasm and nucleus in the HCC827/ER and GR sub-lines. In the H1975/OR sub-line YAP was more predominantly localized to the nucleus than in the cytoplasm (Figure 3).

**Silencing of YAP restores drug-resistant cells sensitive to EGFR inhibitors**

To further understand and evaluate YAP overexpression in relation to drug-resistance in HCC827 ER/GR and expression in H1957/OR we conducted knockdown using siRNA targeting YAP. Western Blot confirmed knockdown prior to evaluating the effects of reintroducing drug to the three drug-resistant cells (Figure 4).

H1975/OR sub-line (Figure 4 A) responded to osimertinib after silencing YAP (p = <0.05). Only 34% of the H1975/OR sub-line cells with YAP silencing siRNA were viable after normalizing to their 10 µM osimertinib negative siRNA controls. HCC827/ER sub-line (Figure 4 B) responded to lower concentrations of erlotinib after silencing YAP (p = <0.05). However, HCC827/GR sub-line showed a reduced response to gefitinib compared with erlotinib-resistant cells but did show significant reduction in cell viability after YAP silencing (p = <0.05) (Figure 4 C).

**DISCUSSION**

Drug resistance is a major cause of cancer treatment failure. Targeted EGFR-directed drugs show effect duration of around one year, where after resistance is inevitable. In this report we show that induction of YAP is a possible mechanism of drug resistance to EGFR tyrosine kinase inhibitors in NSCLC adenocarcinomas, and that inhibiting this co-transcription factor can re-sensitize the cells to EGFR inhibitors.

We exposed the HCC827 cell line to two first generation EGFR inhibitors, erlotinib and gefitinib, and H1975 to osimertinib (AZD9291) and found AXL, a known mechanism of EGFR-TKI-resistance [6] to be expressed in all sub-lines. This was an interesting observation as previous studies have shown that YAP may regulate AXL expression in lung adenocarcinomas [9] and in hepatocellular carcinoma by way of TEAD binding to the promoter region of the AXL gene [12]. Thus YAP expression and activation may be a reason for AXL induction in drug-resistant adenocarcinomas and some other cancer types; though we did not evaluate AXL expression following YAP knockdown, which would have been interesting. Future studies should investigate if YAP inhibition contributes to the reduced capability of AXL signalling which could be clinically exploited in drug-resistant cells.

We also observed a reduced band intensity of EGFR in the HCC827/ER and GR sub-lines compared to the parental (figure 2). This may indicate internalization and...
degradation of EGFR after erlotinib and gefitinib binding. Sakuma et al observed the down-regulation of EGFR after generating gefitinib-resistant HCC4006 adenocarcinoma cells – also harbouring the exon 19 E746-A750 deletion – but not in the HCC827 gefitinib-resistant sub-line [13]. This was concluded to be due to autophagocytosis and may explain why we also see this in our results after acquiring resistance to erlotinib and gefitinib. If this is also observed in the clinic it would be interesting to determine if this is also a prognostic marker of patient outcome.

We noted that the H1975/OR sub-line had a suppressed e-cadherin expression along with reduced expression of vimentin, while HCC827/ER and GR sub-lines expressed vimentin and down-regulated E-cadherin (figure 2). E-cadherin has been found to regulate the phosphorylation of YAP and promote its degradation by way of activating protein 14-3-3 localizing it to the cytoplasm and preventing the binding to TEAD [14]. Loss of the trans-cellular E-cadherin results in epithelial-mesenchymal transition and contact independent growth, migration and invasion. Vimentin induces morphological changes and increases cell motility [15]. It is conceivable that osimertinib may have off targets effecting the transcription of vimentin.

We further evaluated YAP expression and amplification in the HCC827/ER, GR and H1957/OR sub-lines. YAP is only active once it has sequestered to the nucleus where it binds to TEAD and begins transcription of cell survival genes and EMT capabilities [16]. We confirmed YAP expression via western blot and RT-qPCR and found YAP was distributed in both cytoplasm and cell nucleus in the HCC827/ER and GR sub-lines, but more localized to the nucleus in the H1975/OR sub-line (figure 3). We therefore suspected that YAP was both over-expressed and active in all drug-resistant sub-lines. This question, however, was limited as we only used one method of identifying YAP localization. We plan to further investigate YAP-TEAD downstream transcription targets such as amphiregulin that YAP-TEAD downstream transcription targets such as amphiregulin, which would also help confirm YAP activation. We will employ these in all further experiments evaluating YAP activity in drug-resistant NSCLC.

We then wanted to determine if YAP was involved in drug-resistance or merely acted as a biomarker. We found that siRNA-induced YAP silencing restored the negative effect of EGFR inhibitors on cell viability. Our results highlight YAP as a possible mechanism of drug resistance also for the third-generation EGFR-inhibitors, and thus confirm and extend the findings by Hsu et al [17] whose group showed HCC827 erlotinib-resistant and H1975 cells to become re-sensitized to erlotinib after YAP

Figure 3: An immunocytochemistry staining showing the localization of YAP in drug-resistant sub-lines. Both HCC827/ER and GR sub-lines show YAP expression distributed in the cytoplasm and nucleus. The H1975/OR sub-line shows YAP staining more focused in the nucleus than the cytoplasm. Scale bar was 10 μm.
was silenced. Another group also found that inhibiting YAP re-sensitized breast cancer cells to chemotherapeutic agents demonstrating YAP’s ability to orchestrate drug-resistance [18]. These, along with our results, demonstrate an emerging role of YAP in drug resistance and increase the possibility of a new therapeutic target of relapsed EGFR tyrosine kinase inhibitors. The use of statins has been studied and shown to be a potent inhibitor of YAP sequestering to the nucleus in breast cancer cell lines [19]. This study showed potential in pre-existing drugs already approved for use in the clinic which can be revaluated into a new role speeding up the use in YAP-driven cancers. We did not evaluate the expression of EMT markers and AXL post YAP silencing, which has limited our results to suggest YAP is involved with orchestrating EMT.

In conclusion, YAP may be a potential central factor in acquired EGFR-TKI resistance, and further work studying in-depth mechanisms of regulation, role in clinical prognostication and response prediction as well as potential interventional approaches are warranted and ongoing. More work will need to be conducted to confirm YAP activation using the limitations from our experiments to unravel more about this co-transcription factor.

MATERIALS AND METHODS

Cell lines and Reagents

HCC827 and H1975 were purchased from ATCC (CRL-2868 and CRL-5908 respectively) and were maintained in RPMI1640 media (R8758, Sigma) supplemented with penicillin-streptomycin (15140-122, Gibco), L-glutamine (G7513, Sigma), and 10% v/v foetal bovine serum (S1810-500, VWR) in a 95% humidified

Figure 4: YAP siRNA knockdown allows re-sensitization to EGFR inhibitors. A. H1975/OR sub-line shows reduced cell viability when re-introduced to osimertinib after YAP silencing, especially evident at doses around 10 µM. B. We observed HCC827/ER respond to erlotinib after siRNA silencing of YAP from 1 µM drug, with gradually pronounced difference from non-silenced cells up 10 µM. C. HCC827/GR sub-line showed decrease in cell viability after the introduction of drug and silencing of YAP. All siRNA knockdown wells were normalised to their negative siRNA drug counterpart and standard error was calculated based upon two repeats. D. siRNA knockdown was confirmed using Western Blot with GAPDH as a loading control. ** p = <0.05.
5% CO₂ atmosphere at 37°C. Erlotinib was purchased from LC Laboratories (E-4007), osimertinib (AZD9291) was bought from MedChem Express (HY-15772), and gefitinib was a kind gift from Solveig Pettersen at the Radium Hospital. All drugs and compounds were diluted in DMSO (D2650, Sigma) and kept at 0.1% v/v or lower in cell culture media.

HCC827 erlotinib-resistant (ER) and gefitinib-resistant (GR) sub-lines were generated by culturing early passage HCC827 parental cells stepwise from their EC₅₀ to above their C₅₀ₐₓ values. HCC827/ER sub-lines were cultured to 3.5 µM Erlotinib and HCC827/GR sub-lines cultured to 2.5 µM Gefitinib; their C₅₀ₐₓ concentrations are 2.5 µM erlotinib [20] and 0.3 µM gefitinib respectively [21]. H1975/OR sub-lines took much longer to establish due to the response to osimertinib. These cells were cultured to 2.5 µM osimertinib stepwise over several months. The C₅₀ₐₓ value for osimertinib is between 2-3 µM [22] and thus sustaining the sub-line at 2.5 µM was deemed acceptable. Analysis of drug-resistance was determined using EC₅₀ data prior to further experiments.

YAP silencing

YAP silencing was achieved using Qiagen FlexiTube siRNA (Qiagen, S10443651) and negative control siRNA (Qiagen, 1022076) diluted in Lipofectamine RNAiMAX (Thermo Fisher, 13778075) and Opti-MEM (Thermo Fisher, 31985070) used as described in the manufacturer’s specifications. Protein knockdown was assessed using Western Blot.

EC₅₀ cell viability assay

Parental cells were assessed for sensitivity to TKI along with their respective TKI-resistant sub-lines. Cells were seeded at a concentration of 5 x 10⁴ into 96 x well plates with their respective media and allowed to adhere overnight. After 24 hours the media was removed and replaced with media containing varying concentrations of erlotinib, gefitinib or osimertinib and DMSO only for control wells at half-log dilutions. DMSO was kept consistent at 0.1% v/v for all treatment groups and controls. A resazurin metabolism assay (R7017, Sigma) was performed by making a 1/20 dilution of 2.3 mg/ml resazurin stock in sterile Dulbecco’s phosphate buffered saline (DPBS) (14190094, Thermo Fisher) and using a 1/10 dilution directly in the wells after 120 hours drug incubation. Resazurin sodium salt was allowed 4 hours incubation at 37°C in a 95% humidified, 5% CO₂ atmosphere. Plates were assessed for active viable cells using fluorescence imager BioTek Synergy 2 with software Gen5 with filters for excitation at 544 nm and emission at 590 nm. The EC₅₀ curve was created using GraphPad v.6 software by normalising the average treatment wells to the DMSO controls. Data was presented as percent of controls.

For siRNA-erlotinib/gefitinib/osimertinib combination, we loaded each well of a 96 well plate with 5 x 10⁴ cells per well and left them to adhere overnight in media with drug. The following day media was changed to media with siRNA YAP or negative control siRNA and allowed to incubate for 48 hours without drug. After 48 hours we added drug dilutions directly onto the siRNA loaded cells and incubated for a further 72 hours before assessing viable cells using the resazurin assay. We normalized each siRNA drug/compound group to the negative groups, for example 10 µM erlotinib YAP siRNA was normalized to 10 µM negative siRNA control. Results were presented as percentages of the negative siRNA in a bar graph with ± SEM and statistical differences between controls and YAP knockdown were conducted using a two-tailed, unpaired and unequal variance student’s T-Test and presented on the graphs.

Immunocytochemistry of YAP

Cells were trypsinized and seeded at a concentration of 10 x 10⁴ onto frosted-coated glass slides and left to adhere overnight at 37°C in a 95% humidified 5% CO₂ incubator. Once adhered, slides were rinsed twice with sterile D-PBS and treated with 0.3% v/v Triton-X100 (T8787, Sigma) for five minutes to permeabilize the cells. Slides were washed three more times before blocking with 5% Goat serum (staining control) for 1 hour at room temperature. Slides were washed three times and treated with Goat Anti-Rabbit IgG Alexa Fluor® 594 conjugated secondary antibody (A-11037, Thermo Fisher) for 60 minutes in the dark at room temperature. Slides were washed another three times and stained with ProLong® Gold Antifade Mountant with DAPI nucleus dye (P36931, Thermo Fisher) for 10 minutes. Slides were mounted and used immediately for imaging and then stored at -20°C in the dark.

Western Blot

Cells were harvested for protein by using Ripa lysis buffer (89901, Thermo Scientific) with 50 mM sodium orthovanadate (S6508, Sigma), 50 mM Pefabloc (1.24839.0500, Merck), 50 mM sodium fluoride (S6508, Sigma), PhosSTOP (04906845001, Roche) and Protease inhibitor cocktail (05892970001, Roche). Protein concentration was measure using the Pierce BCA kit (23227, Thermo Scientific) at the manufacturer’s specifications. A concentration of 15 µg protein lysate was boiled with Laemmli sample buffer (161-0747, Bio-Rad) with 100 mM DTT (A3668, AppliChem) for
five minutes at 95°C then loaded into a 12% SDS mini-
PROTEAN® TGX™ gel (456-1046, Bio-Rad) and ran
for 60 minutes at 200 v. Gels were transferred to a Midi
Format nitrocellulose membrane (1704159, Bio-Rad)
using a Turbo blot transfer module form Bio-Rad. The
membranes were blocked for 60 minutes in (1706404,
Bio-Rad) 0.1% Tween 20 (1610781, Bio-Rad) diluted
in Tris buffered saline (1706435, Bio-Rad) containing
5% v/v fat-free milk. Membranes were washed for five
minutes three times in 0.1% TTBS before sectioning and
incubating overnight at 4°C rotating in primary
antibodies: Axl (8661, Cell Signalling), EGFR (4267, Cell
Signalling), Merlin (PA5-35316, Thermo Scientific), YAP
(PA5-13504, Thermo Scientific), E-Cadherin (ab1416,
Abcam), Vimentin (ab92547, Abcam) and GAPDH for
loading control (MAB374, Millipore). Membranes were
washed three times for five minutes in 0.1%
TTBS before incubating with secondary antibodies for 60 minutes
at room temperature in either peroxidase-conjugated Goat
anti-Mouse (31431, Thermo Scientific) or Goat anti-
Rabbit (31466, Thermo Scientific). Membranes were
washed another three times for five minutes in 0.1%
TTBS and developed using SuperSignal® (34095, Thermo
Scientific) and being viewed using the Bio-Rad Chemi
Doc™ MP imager running Image Lb v4.1 software.

Abbreviations

Epidermal growth factor receptor (EGFR), Epithelial to mesenchymal transition (EMT), Yes-
associated protein (YAP).

ACKNOWLEDGMENTS AND FUNDING

The Authors wish to thank, Inga H. Rye, Daniel Nebdal, Jodie Peter Goodridge, Kishan Jumar Chudasama
and Ellen Tenstad for their help, advice and training during this project. The project was funded by a research grant
from Helse Sør-øst.

CONFLICTS OF INTEREST

The Authors declare no conflict of interests.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers
C, Rebelo M, Parkin DM, Forman D and Bray F. Cancer
incidence and mortality worldwide: Sources, methods and
major patterns in GLOBOCAN 2012. International Journal
of Cancer. 2015; 136(5): E359-E386.
2. Brustugun OT. Stratification in advanced non-small cell
lung cancer: precision medicine in practice. Expert Review
of Precision Medicine and Drug Development. 2016;
1(3):279-287.
3. Russo A, Franchina T, Rita Ricciardi GR, Picone A,
Ferraro G, Zanghi M, Toscano G, Giordano A and Adamo
V. A decade of EGFR inhibition in EGFR-mutated non
small cell lung cancer (NSCLC): Old successes and future
perspectives. Oncotarget. 2015; 6(29):26814-25.
4. Kuiper JL, Heideman DAM, Thunnissen E, Paul MA, van
Wijk AW, Postmus PE and Smit EF. Incidence of T790M
mutation in (sequential) rebiopsies in EGFR-mutated
NSCLC-patients. Lung Cancer. 2014; 85(1):19-24.
5. Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR,
Ramalingam SS, Shepherd FA, He Y, Akamatsu H,
Theelen WSME, Lee CK, Sebastian M, Templeton A, et
al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–
Positive Lung Cancer. New England Journal of Medicine.
2017; 376(7):629-640.
6. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T,
Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ,
Choi C-M, Kim S-W, et al. Activation of the AXL kinase
causes resistance to EGFR-targeted therapy in lung cancer.
Nature Genetics. 2012; 44(8):852-860.
7. Bean J, Brennan C, Shih J, Riely G, Viale A, Wang L,
Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang
W, Yu C, et al. MET amplification occurs with or without
T790 M mutations in EGFR mutant lung tumors with
acquired resistance to gefitinib or erlotinib. Proc Natl Acad
Sci USA. 2007; 104:20932 - 20937.
8. Engelman J, Zejnullahu K, Mitsudomi T, Song Y, Hyland C,
Park J, Lindeman N, Gale C, Zhao X, Christensen J, Kosaka
T, Holmes A, Rogers A, et al. MET amplification leads to
gefitinib resistance in lung cancer by activating ERBB3
signaling. Science. 2007; 316:1039 - 1043.
9. Cui Z-L, Han F-F, Peng X-H, Chen X, Luan C-Y, Han R-C,
Xu W-G and Guo X-J. Yes-Associated Protein 1 Promotes
Epidermal growth factor receptor (EGFR), Epithelial to mesenchymal transition (EMT), Yes-
associated protein (YAP).
14. Kim N-G, Koh E, Chen X and Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proceedings of the National Academy of Sciences. 2011; 108(29):11930-11935.

15. Mendez MG, Kojima S-I and Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. The FASEB Journal. 2010; 24(6):1838-1851.

16. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang C-Y, Chinnaiyan AM, Lai Z-C and Guan K-L. TEAD mediates YAP-dependent gene induction and growth control. Genes & Development. 2008; 22(14):1962-1971.

17. Hsu P-C, You B, Yang Y-L, Zhang W-Q, Wang Y-C, Xu Z, Dai Y, Liu S, Yang C-T, Li H, Hu B, Jablons DM and You L. YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget. 2016; 7(32): 51922–51933.

18. Oku Y, Nishiya N, Shito T, Yamamoto R, Yamamoto Y, Oyama C and Uehara Y. Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio. 2015; 5:542-549.

19. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, Rosato A, Piccolo S and Del Sal G. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014; 16(4):357-366.

20. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K and Cagnoni PJ. Effects of smoking on the pharmacokinetics of erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(7 Pt 1):2166-2171.

21. Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH and Duvauchelle T. Single-Dose Clinical Pharmacokinetic Studies of Gefitinib. Clinical Pharmacokinetics. 2005; 44(11):1165-1177.

22. Jänne PA, Yang JC-H, Kim D-W, Planchard D, Ohe Y, Ramalingam SS, Ahn M-J, Kim S-W, Su W-C, Horn L, Haggstrom D, Felip E, Kim J-H, et al. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2015; 372(18):1689-1699.